Literature DB >> 1877400

Studies on the mechanisms of inhibition of L1210 cell growth by 3,4-dihydroxybenzohydroxamic acid and 3,4-dihydroxybenzamidoxime.

T Tihan1, H L Elford, J G Cory.   

Abstract

Didox and Amidox inhibit L1210 cell growth in culture. At least one of the mechanisms in the mode(s) of action of the compounds is directed at the ribonucleotide reductase site. Partially purified preparations of ribonucleotide reductase activity are inhibited by Amidox and Didox. The formation of deoxycytidine nucleotides from [14C]cytidine in intact L1210 cells is also blocked. Didox and Amidox cause the decrease in the intracellular pools of the four dNTPs. Hydroxyurea-resistant L1210 cells are not cross-resistant to either Didox or Amidox. These data suggest that Didox and Amidox are not inhibiting ribonucleotide reductase through a mechanism similar to hydroxyurea.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1877400     DOI: 10.1016/0065-2571(91)90009-b

Source DB:  PubMed          Journal:  Adv Enzyme Regul        ISSN: 0065-2571


  4 in total

1.  The Epstein-Barr virus (EBV) deubiquitinating enzyme BPLF1 reduces EBV ribonucleotide reductase activity.

Authors:  Christopher B Whitehurst; Shunbin Ning; Gretchen L Bentz; Florent Dufour; Edward Gershburg; Julia Shackelford; Yves Langelier; Joseph S Pagano
Journal:  J Virol       Date:  2009-02-25       Impact factor: 5.103

Review 2.  Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present.

Authors:  Sarah E Huff; Jordan M Winter; Chris G Dealwis
Journal:  Biomolecules       Date:  2022-06-10

3.  Synthesis and testing of new antileukemic Schiff bases of N-hydroxy-N'-aminoguanidine against CCRF-CEM/0 human leukemia cells in vitro and synergism studies with cytarabine (Ara-C).

Authors:  P B Koneru; E J Lien; V I Avramis
Journal:  Pharm Res       Date:  1993-04       Impact factor: 4.200

4.  Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase.

Authors:  T Szekeres; K Gharehbaghi; M Fritzer; M Woody; A Srivastava; B van't Riet; H N Jayaram; H L Elford
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.